Successful treatment of disseminated interdigitating dendritic cell sarcoma with adriamycin, bleomycin, vinblastine, and dacarbazine chemotherapy.
10.5045/kjh.2012.47.2.150
- Author:
Suk Young LEE
1
;
Se Ryeon LEE
;
Won Jin CHANG
;
Hye Sook KIM
;
Byung Soo KIM
;
In Sun KIM
Author Information
1. Department of Hemato-oncology, Korea University Medical Center, Anam Hospital, Seoul, Korea.
- Publication Type:Case Report
- Keywords:
IDCS;
ABVD chemotherapy;
Complete remission
- MeSH:
Antigen-Presenting Cells;
Antigens, CD45;
Biopsy;
Bleomycin;
Dacarbazine;
Dendritic Cell Sarcoma, Interdigitating;
Dendritic Cells;
Humans;
Middle Aged;
Nasal Cavity;
S100 Proteins;
Turbinates;
Vinblastine
- From:Korean Journal of Hematology
2012;47(2):150-153
- CountryRepublic of Korea
- Language:English
-
Abstract:
Interdigitating dendritic cell sarcoma (IDCS) is a very rare and aggressive neoplasm that arises from antigen presenting cells. IDCS usually involves lymph nodes; however, extra-nodal involvement has also been reported. Because a consistent standard therapy for IDCS has not been established to date, we report a case of the successful treatment of disseminated IDCS using ABVD chemotherapy (doxorubicin, bleomycin, vinblastine, and dacarbazine). A 64-year-old man was diagnosed with IDCS on the basis of immunohistochemical findings of a biopsy specimen of the inferior nasal concha. Immunohistochemical staining showed a positive reaction for CD68, leukocyte common antigen, and S-100 protein, but a negative reaction for CD34, CD1a, and CD21. Imaging studies showed cervical and axillary lymphadenopathies, subcutaneous nodules, and a soft tissue lesion in the nasal cavity. Treatment with the ABVD regimen resulted in complete remission after 8 cycles of chemotherapy.
